Abstract:BackgroundThe antitumor effects of natural killer cells, helper T cells, and cytotoxic T cells after cancer surgery were reported previously. This study hypothesized that propofol-based anesthesia would have fewer harmful effects on immune cells than volatile anesthetics–based anesthesia during colorectal cancer surgery.MethodsIn total, 153 patients undergoing colorectal cancer surgery were randomized and included in the analysis. The primary outcome was the fraction of circulating natural killer cells over time in the propofol and sevoflurane groups. The fractions of circulating natural killer, type 1, type 17 helper T cells, and cytotoxic T cells were investigated. The fractions of CD39 and CD73 expressions on circulating regulatory T cells were investigated, along with the proportions of circulating neutrophils, lymphocytes, and monocytes.ResultsThe fraction of circulating natural killer cells was not significantly different between the propofol and sevoflurane groups until 24 h postoperatively (20.4 ± 13.4% vs . 20.8 ± 11.3%, 17.9 ± 12.7% vs . 20.7 ± 11.9%, and 18.6 ± 11.6% vs . 21.3 ± 10.8% before anesthesia and after 1 and 24 h after anesthesia, respectively; difference [95% CI], –0.3 [–4.3 to 3.6], –2.8 [–6.8 to 1.1], and –2.6 [–6.2 to 1.0]; P = 0.863, P = 0.136, and P = 0.151 before anesthesia and after 1 and 24 h, respectively). The fractions of circulating type 1 and type 17 helper T cells, cytotoxic T cells, and CD39 + and CD73 + circulating regulatory T cells were not significantly different between the two groups. The neutrophil to lymphocyte ratio in both groups remained within the normal range and was not different between the groups.ConclusionsPropofol-based anesthesia was not superior to sevoflurane-based anesthesia in terms of alleviating suppression of immune cells including natural killer cells and T lymphocytes during colorectal cancer surgery.Editor's PerspectiveWhat We Already Know about This Topic Experimental studies alongside clinical trials yielded contradictory observations on the potential antitumor effects of intravenous- versus volatile anesthetics–based anesthesia regimens in the context of colorectal cancer surgery Various immune cells have been suggested to exert antitumor effects during the perioperative period The question whether propofol- versus sevoflurane-based anesthesia differentially affects circulating immune cells during colorectal cancer surgery is incompletely explored What This Article Tells Us That Is New In this randomized controlled trial, the fraction of circulating natural killer cells and T lymphocytes was comparable between propofol- and sevoflurane-based anesthesia in patients undergoing colorectal cancer surgery These observations suggest that the type of general anesthetics used may minimally affect perioperative immune status

Propofol Stimulates Immune Activity and Decreases Inflammatory Cytokines via NF-κB-Mediated JAK1-STAT3 Pathway in Gastric Cancer Patients Undergoing Radical Surgery

Propofol Inhibits Proliferation, Migration, Invasion and Promotes Apoptosis Through Down-Regulating Mir-374A in Hepatocarcinoma Cell Lines

Effects of Propofol on Colon Cancer Metastasis Through STAT3/HOTAIR Axis by Activating WIF‐1 and Suppressing Wnt Pathway

Propofol Exerts Anti-Hepatocellular Carcinoma by Microvesicle-Mediated Transfer of Mir-142-3p from Macrophage to Cancer Cells

Propofol Inhibits the Adhesion of Hepatocellular Carcinoma Cells by Upregulating Microrna-199A and Downregulating MMP-9 Expression.

Propofol Facilitates Cisplatin Sensitivity Via Lncrna MALAT1/miR-30e/ATG5 Axis Through Suppressing Autophagy in Gastric Cancer.

The Inhibitory Effects of Propofol on Colorectal Cancer Progression through the NF-κB/HIF-1α Signaling Pathway

Expression Profiles of Immune Cells after Propofol or Sevoflurane Anesthesia for Colorectal Cancer Surgery: A Prospective Double-blind Randomized Trial

Suppressive effect of the anesthetic propofol on the T cell function and T cell-dependent immune responses

Propofol maintains Th17/Treg cell balance in elderly patients undergoing lung cancer surgery through GABAA receptor

Propofol Pretreatment Prevents Oxygen-Glucose Deprivation/Reoxygenation (OGD/R)-induced Inflammation Through Nuclear Transcription Factor κB (NF-κB) Pathway in Neuroblastoma Cells

Propofol suppresses proliferation and metastasis of colorectal cancer cells by regulating miR-124-3p.1/AKT3

Influences of Etomidate Combined with Propofol on Cognitive Function, Inflammation and Immunity in Patients Undergoing Gastric Cancer Surgery

Gaba-Receptor Agonist, Propofol Inhibits Invasion Of Colon Carcinoma Cells

Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer

Lung but not brain cancer cell malignancy inhibited by commonly used anesthetic propofol during surgery: Implication of reducing cancer recurrence risk

Effect of Propofol on breast Cancer cell, the immune system, and patient outcome

Effect of Perioperative Autologous Versus Allogeneic Blood Transfusion on the Immune System in Gastric Cancer Patients

Effects of Dexmedetomidine and Propofol on Postoperative Analgesia and the Cellular Immune Function of Patients Undergoing Radical Gastrectomy for Gastric Cancer

Effects of propofol intravenous general anesthesia and inhalational anesthesia on T-lymphocyte activity after breast cancer surgery: A meta-analysis

Effects of propofol on the development of cancer in humans